The introduction of the Torin Artificial Intelligence (AI) functionality is designed to improve efficiency in managing schedules for surgical procedures and comes in the wake of a new Getinge survey. Among the participating hospitals 41% report significant backlogs and only 44% have implemented new digital tools that can improve proficiency in OR scheduling and patient management. Getinge, a leading global provider of products and solutions that contribute to quality enhancement and cost efficiency within healthcare and life sciences, now introduces Torin with AI in the United States. The company also announced results from a landmark survey of hospital executives and surgeons in the U.S. showing hospitals are taking steps to speed up OR turnover times, hire new staff and require staff to work longer hours to address backlogs. "For almost 18 months during the COVID-19 pandemic, both surgeons and patients made decisions to defer many forms of surgery if possible. As more patients feel confident about considering surgery, demand to schedule procedures at all types of hospitals and surgery centers has exploded in recent months," says Eric Honroth, President, North America at Getinge.
Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence (AI) in Operating Room Market: Focus on Offering, Technology, Indication, Application, End User, Unmet Demand, Cost-Benefit Analysis, and Over 16 Countries' Data - Analysis and Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The purpose of the study is to enable the reader to gain a holistic view of the global AI in the operating room market by each of the aforementioned segments. The report constitutes an in-depth analysis of the global AI in the operating room market, including a thorough analysis of the applications. The study also provides market and business-related information on various products, applications, technologies, and end users. The report considers software solutions and hardware solutions integrated with AI. "I think these are exciting times. Not considering the buzz around AI, ultimately, it is an enabler to do things at scale and quickly. It needs to serve a higher purpose that provides surgeons or other stakeholders in the healthcare ecosystem with value. The real value that a company provides with AI is the key component. This technology can be leveraged to tackle the disparity in the world of surgery".
Artificial intelligence (AI) is a buzzword in tech these days. The term, which encompasses a range of technologies including machine learning and data analysis. The goal is to create systems that can perceive, learn, and reason in ways that mimic human capabilities. At its best, AI will allow machines to understand the gestalt of a situation and react accordingly, a capability that humans take for granted – but has tends to elude computer systems, which in their turn excel at analyzing minute details. A wide range of tech companies are working on AI systems; artificial intelligence holds the promise of real-time data analysis and situation monitoring, with the machines capable of handling routine decisions. While it hasn’t been achieved yet, the outlines of success are visible on the horizon. Every smart investor knows to keep his eyes on the horizon; that is, to plan every investment with long-range intentions. Just how long is up to the individual, but most investors agree that a move isn’t long-term unless it’s held for more than one year. Warren Buffett has famously said, “If you are not willing to own a stock for 10 years, do not even think about owning it for 10 minutes.” With this in mind, we used TipRanks' database to identify three AI stocks that have been highlighted by some of Wall Street’s best tech sector analysts. These are analysts with 5-star ratings, standing above their peers in accuracy and average returns – and they’ve tapped Artificial Intelligence as a tech segment for the long run. Veritone, Inc. (VERI) We’ll start with Veritone. This media tech company offers a cloud-based operating system for AI that uses machine learning to turn data into useful intelligence. The software allows users to process audio and video in real time, enhance analytics and research apps, reduce content review times, and streamline time spent on ‘low-value, high-effort’ tasks. The value of the product to the customers can be seen in the quarterly earnings trends and the share appreciation. The last six months – covering the worst of the global pandemic and economic recessionary pressures – have seen VERI’s earnings steadily improve and the share price rise to its best level in over two years. Earlier this month, Veritone showed its confidence by adjusting its Q2 revenue guidance upwards. The guidance, of $13.1 to $13.3 million, is well above the previous upper guide of $12.2 million. The share price has tracked the gains in revenue and earnings. The stock has more than doubled since the February/March market collapse, rising from $3.03 to $10.83 now. Patrick Walravens, writing from JMP Securities, was impressed by Veritone’s new revenue guidance, and reiterated his Buy rating on the stock. In his comments, he said, “Veritone seems to be gaining traction in its Government, Legal, and Compliance verticals as it experienced record bookings in the quarter… we believe the company is moving its cost structure in the right direction with recent cost-reduction initiatives and upgrades…” With his $17 price target, Walravens shows his own confidence that VERI will see 57% growth in the year ahead. (To watch Walravens’ track record, click here) Overall, VERI’s Moderate Buy analyst consensus rating is based on 4 Buys and just a single Sell. The stock’s current price is $11.80, and the average price target $16.25 suggests it has a 50% upside potential. Note that even the low-ball target estimate, of $15, is well above the current price. (See Veritone stock analysis on TipRanks) ZoomInfo Technologies (ZI) Next up is ZoomInfo, a marketing tech company. ZI offers the usual features and services that customers expect in digital marketing intelligence, including account management, data management, demand generation, and lead prospecting. The company’s AI cloud software is specifically designed to improve efficiency in these tasks, letting sellers get to the business of selling. ZoomInfo is a newly public company, having held its IPO just this past June. The opening was a success, with share prices almost doubling on the first day and nearly tripling in the first few trading sessions. Even now, after nearly two months during which the initial excitement waned and the glow came off the rose, the stock is still trading 88% above its initial price of $21. The strong IPO prompted SunTrust Robinson analyst Terry Tillman – who is rated in the top 10 of the TipRanks analyst database – to initiate coverage of the stock with a Buy rating. Tillman wrote of ZoomInfo, “We believe ZoomInfo represents a rare combination of strong top-line growth and best-in-class profitability. Its go-to-market (GTM) sales intelligence platform drives positive outcomes for B2B sales and marketing organizations - increasing leads, customers and revenue. Premium valuation justified owing to accelerating demand for GTM intelligence and company-specific drivers leading to significant revenue and profit upside.” Tillman’s Buy rating comes with a $60 price target, implying an impressive 51% upside potential. (To watch Tillman’s track record, click here) ZoomInfo holds a Moderate Buy rating from the analyst consensus. This is based on 16 reviews, including 7 Buys and 9 Holds. The stock’s $55.07 average price target suggests it has room for 32% growth from the $41.66 trading price this year. (See ZoomInfo stock analysis on TipRanks) CareDx (CDNA) Last on today’s list is a tech company in the health care sector. CareDx develops and delivers diagnostic surveillance systems for heart transplant patients. The company’s AI-powered software monitors patient progress in real time, allowing both the patient and the doctors to respond to any rapidly changing health issues in time to ensure a more successful outcome. The result is a novel development in long-term care. While CareDx’s products were originally designed to monitor heart transplants, the company has expanded. Its products now monitor most human organ transplants – including kidneys, an important niche, as the first successful organ transplant was conducted with a kidney, and this procedure is still among the most common of transplants. CareDx also has cloud-based AI systems to monitor lab results, and to connect digital implants with remote monitors. The company’s earnings have proven mostly immune to recent economic instability, as medical transplant patients and doctors cannot simply stop using the monitoring systems. And with a firm user base, the stock recovered well from the late-winter market crash. CDNA is up over 130% since bottoming out in March. Covering the stock for Piper Sandler, analyst Steven Mah wrote, “We believe CareDx has the broadest transplant care platform in the industry and we remain confident that it is well-positioned to protect and extend its first-mover advantage in both pre- and post-transplant patient management to drive long-term growth. In addition, we are encouraged by the resiliency of its essential tests and ability to operate in a COVID-19 environment.” Mah gives CDNA a Buy rating, along with a $54 price target that implies an upside of 66% for the next 12 months. (To watch Mah’s track record, click here) All in all, with 4 recent reviews on record, all Buys, CareDx has a unanimous Strong Buy rating from the analyst consensus. The stock is currently selling for $32.59, and the average price target, at $42.75, suggests a one-year upside of 31%. (See CareDx stock-price forecast on TipRanks) To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Medtronic and Medicrea announced in a press release that they are in the process of finalizing the acquisition by the US company of the Lyon-based SME. The latter is one of the pioneers in transforming spinal surgery through artificial intelligence, predictive modeling and customized spinal implants. The agreement between the two players will be achieved through the acquisition by Medtronic of all outstanding Medicrea shares. With a focus on predictive medicine, Medicrea designs, manufactures and distributes more than 30 families of FDA-approved implantable devices, which have been used in more than 175,000 surgical procedures worldwide to date. Medicrea is a Lyon-based SME with 175 employees, 35 of whom work in its subsidiary Medicrea USA Corp. based in New York. The company has its own ultra-modern production unit in Lyon, dedicated to the machining and development of custom implants by 3D printing from titanium powder.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, and KenSci, a healthcare artificial intelligence (AI) platform company, announced today that a collaborative, foundational study on using machine learning (ML) to predict outcomes after shoulder arthroplasty has been published in Clinical Orthopaedics and Related Research, one of the premier scientific journals in orthopaedics. The research analyzes the potential of ML to use preoperative data to anticipate patients' post-operative results after anatomic total shoulder arthroplasty (aTSA) or reverse total shoulder arthroplasty (rTSA). These results can help surgeons preoperatively identify if a patient will achieve certain clinical improvement thresholds to appropriately risk-stratify patients for these elective procedures. Specifically, this research explores the efficacy of ML to predict the American Shoulder and Elbow Surgery (ASES), Constant, global shoulder function and VAS pain score, as well as to predict a patient's active range of motion in abduction, forward flexion and external rotation. This research also studies the ability of ML to identify if a patient may achieve clinical improvement that exceeds the minimal clinically important difference threshold as well as the substantial clinical benefit threshold for each outcome measure.
Origami Surgical last week filed an SEC Form D to confirm the sale of more than $2.2 million in an equity offering.The Madison, N.J.-based company, founded this year, filed a new notice for the sale of equity on March 23, 2020, with the intention of the offering lasting less than a year. According to the Form D filing, Origami Surgical's offering is not being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer. Two investors contributed to the sale of $2,224,998 in the equity offering that is set to bring in $2,499,996, leaving $274, 998 left to be sold. Origami Surgical did not list an intended use of proceeds. The company develops the StitchKit, which it touts as the first suture system designed to improve endoscopic robotic surgery outcomes by increasing efficiency, autonomy and safety, according to the company website.
Digital Surgery, a health tech startup based in London, today launched what it's calling the world's first dynamic artificial intelligence (AI) system designed for the operating room. The reference tool helps support surgical teams through complex medical procedures -- cofounder and former plastic surgeon Jean Nehme described it as a "Google Maps" for surgery. "What we've done is applied artificial intelligence … to procedures … created with surgeons globally," he told VentureBeat in a phone interview. "We're leveraging data with machine learning to build a [predictive] system." Well-funded hospital systems have shown an interest in automation.
LONDON–(BUSINESS WIRE)–Digital Surgery, a health tech company shaping the future of surgery through the convergence of surgical expertise and technology, today announced it has developed and successfully demonstrated the world's first real-time, dynamic artificial intelligence (AI) system designed for the operating room (OR). The company is building the data to power the future of surgery through its world-class and proprietary surgical procedure road maps, which aim to aid the surgical team in the OR, reducing risk and making surgery safer. Digital Surgery is the first patented AI platform bringing this scale of knowledge to the surgical community. "This is a huge milestone for the future of surgery because it lays the foundation for how AI and computer vision will support surgical teams to deliver safer surgeries. It also enables the next generation of robotic surgery, giving these future systems the capability to function more intelligently and safely," said Dr. Jean Nehme MD, co-founder and CEO of Digital Surgery.
LONDON--(BUSINESS WIRE)--Digital Surgery, a health tech company shaping the future of surgery through the convergence of surgical expertise and technology, today announced it has developed and successfully demonstrated the world's first real-time, dynamic artificial intelligence (AI) system designed for the operating room (OR). The company is building the data to power the future of surgery through its world-class and proprietary surgical procedure road maps, which aim to aid the surgical team in the OR, reducing risk and making surgery safer. Digital Surgery is the first patented AI platform bringing this scale of knowledge to the surgical community. "This is a huge milestone for the future of surgery because it lays the foundation for how AI and computer vision will support surgical teams to deliver safer surgeries. It also enables the next generation of robotic surgery, giving these future systems the capability to function more intelligently and safely," said Dr. Jean Nehme MD, co-founder and CEO of Digital Surgery.
April 29, 2016 - With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning--a subfield of artificial intelligence--to improve medical care and patient outcomes. An overview of machine learning and some of the ways it could contribute to advancements in plastic surgery are presented in a special topic article in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). "Machine learning has the potential to become a powerful tool in plastic surgery, allowing surgeons to harness complex clinical data to help guide key clinical decision-making," write Dr. Jonathan Kanevsky of McGill University, Montreal, and colleagues. They highlight some key areas in which machine learning and "Big Data" could contribute to progress in plastic and reconstructive surgery. Machine learning analyzes historical data to develop algorithms capable of knowledge acquisition.